We present the first study demonstrating the value of a combined MAO-B and tau radioligand for the differential diagnosis of neurodegenerative parkinsonian syndromes including primary tauopathies (PSP) and α-synucleinopathies (PD, MSA). Here, MAPT is linked to supranuclear palsy, progressive, 1.